Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients.

Kakinami L, Adams MJ, Block RC, Cohn SE, Maliakkal B, Fisher SG.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1552-6. doi: 10.1089/AID.2011.0392. Epub 2012 Apr 10.

2.

Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.

Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, Muñoz A, Domingo P, Ribera E, Cosín J, Viciana P, Lozano F, Terrón A, Vergara A, Teira R, Muñoz-Sánchez J, Roca B, Sánchez T, López-Aldeguer J, Deig E, Vidal F, Pedrol E, Castaño-Carracedo M, Puig T, Garrido M, Suárez-Lozano I.

BMC Womens Health. 2011 Aug 4;11:36. doi: 10.1186/1472-6874-11-36.

3.

HIV/hepatitis C virus-coinfected patients: is there a better marker for atherogenicity?

Manickam P, Mogrovejo E, Krishnamoorthi R.

AIDS Res Hum Retroviruses. 2013 May;29(5):745. doi: 10.1089/AID.2012.0366. Epub 2013 Feb 5. No abstract available.

PMID:
23289614
4.

Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.

Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, Kigozi A, Borkowf CB, Ndazima V, Brooks JT.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):304-11.

PMID:
18398971
5.

Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.

Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A.

HIV Med. 2007 Jul;8(5):280-7.

6.

HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.

Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D.

Metabolism. 2006 Jan;55(1):90-5.

PMID:
16324925
7.

Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.

Langat A, Benki-Nugent S, Wamalwa D, Tapia K, Ngugi E, Diener L, Richardson BA, Melvin A, John-Stewart GC.

Pediatr Infect Dis J. 2013 Jul;32(7):e298-304. doi: 10.1097/INF.0b013e31828afb2a.

8.

Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.

Biron A, Bobin-Dubigeon C, Volteau C, Piroth L, Perré P, Leport C, Prazuck T, Jovelin T, Billard M, Sébille V, Bard JM, Raffi F, Biron C.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1672-8. doi: 10.1089/AID.2012.0048. Epub 2012 Jul 25.

PMID:
22731114
9.

Impact of HIV infection and HAART on serum lipids in men.

Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA.

JAMA. 2003 Jun 11;289(22):2978-82.

PMID:
12799406
10.

Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.

Chen TY, Ding EL, Seage Iii GR, Kim AY.

Clin Infect Dis. 2009 Nov 15;49(10):1605-15. doi: 10.1086/644771.

11.

Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.

Patroni A, Torti C, Tomasoni L, Quiros Roldan E, Bertelli D, Puoti M, Cadeo GP, Sleiman I, Tinelli C, Carosi G, Castelli F.

HIV Clin Trials. 2002 Nov-Dec;3(6):451-61.

PMID:
12501128
12.

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study.

Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5. doi: 10.1097/QAI.0b013e31815d2f59.

PMID:
18223361
13.

rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.

Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, Carrero A, García-Álvarez M, Aldámiz-Echevarria T, García-Broncano P, Diez C, Guzmán-Fulgencio M, Fernández-Rodríguez A, Resino S.

AIDS Res Hum Retroviruses. 2015 Mar;31(3):326-34. doi: 10.1089/aid.2014.0195. Epub 2014 Oct 29.

14.

Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.

Kang F, Chen W, Zhang X, Nie W, Fu J, Xu X, Zhao P, Zhang X, Li W, Wang FS, Zhang Z, Zhao M.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):135-42. doi: 10.1097/QAI.0b013e3182752d20.

PMID:
23075912
15.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
16.

Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?

Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M.

Clin Infect Dis. 2006 Jan 15;42(2):262-70. Epub 2005 Dec 2.

PMID:
16355339
17.

Metabolic changes associated with antiretroviral therapy in HIV-positive patients.

Almeida SE, Borges M, Fiegenbaum M, Nunes CC, Rossetti ML.

Rev Saude Publica. 2009 Apr;43(2):283-90. Epub 2009 Feb 13.

18.

Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy.

Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):245-50.

PMID:
11464143
19.

Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy.

Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO, Chang SW.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):613-9.

PMID:
16044016
20.

Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis.

Miller MF, Haley C, Koziel MJ, Rowley CF.

Clin Infect Dis. 2005 Sep 1;41(5):713-20. Epub 2005 Jul 22.

PMID:
16080095

Supplemental Content

Support Center